We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.15 | -0.78% | 145.675 | 146.88 | 145.35 | 146.88 | 2,102,743 | 16:10:35 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Pulmatrix Inc. on Monday said Johnson & Johnson has terminated its lung-cancer license, development and commercialization agreement with the company.
The Lexington, Mass., clinical-stage biopharmaceutical company said that as a result of the termination, it will regain full rights to its narrow spectrum kinase inhibitor portfolio, including PUR1800.
Pulmatrix early last year announced the agreement with J&J's Lung Cancer Initiative under which the company received a $7.2 million upfront payment and was eligible for more than $90 million in milestone payments.
Pulmatrix said it plans to continue the development of PUR1800, with ongoing clinical and toxicology studies to support programs in acute exacerbations in chronic obstructive pulmonary disease and other chronic airway diseases.
Pulmatrix shares, which closed Friday at $1.29, fell more than 10% in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 12, 2021 09:39 ET (13:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
